Athanor Capital’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Athanor Capital’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-6,420	Closed	-$550K	–	1139
2020 Q4	$550K	Buy	+6,420	New	+$544K	0.01%	444
2020 Q3	–	Sell	-3,665	Closed	-$268K	–	737
2020 Q2	$268K	Buy	+3,665	New	+$195K	0.01%	433
2020 Q1	–	Sell	-6,700	Closed	-$365K	–	435
2019 Q4	$365K	Sell	6,700 -7,200	-52%	-$357K	0.02%	283
2019 Q3	$580K	Buy	13,900 +9,200	+196%	+$389K	0.04%	143
2019 Q2	$206K	Buy	+4,700	New	+$265K	0.03%	127

Other funds holding BHVN

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Athanor Capital's BHVN Position: Q1 2021 in Review

Athanor Capital sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q1 2021, closing a stake of 6,420 shares — an estimated $550K sold.

Athanor Capital first reported a position in BHVN in Q2 2019 and held it in 5 quarters. The position peaked at $580K in Q3 2019. 224 funds tracked by Wall St. Rank hold BHVN as of Q1 2021.

Athanor Capital reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q1 2021 after selling out during the quarter.
Athanor Capital sold 6,420 Biohaven Pharmaceutical Holding Company Ltd. shares in Q1 2021, an estimated $550K.
Athanor Capital first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2019 and held it in 5 quarters.
Athanor Capital's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $580K in Q3 2019.
224 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q1 2021.

Based on Athanor Capital's 13F filing for Q1 2021, filed 14 May 2021.